National Institutes of Health intends to procure from RhodeIsland Hospital, Providence, RI a trial of penicillin prophylaxis for the Pandas subgroup that shall include at a minimum, but not be limited to, the following characteristics and features: (1) This trial shall determine if penicillin prophylaxis is superior to placebo in preventing group A streptococcal (GAS) associated neuropsychiatric exacerbations in children in the Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal (PANDAS) subgroup; (2) Shall determine how penicillin prophylaxis changes the course of illness for patients in the PANDAS subgroup; (3) Shall recruit and follow up to 20 children in the PANDAS subgroup who are randomized to receive either penicillin or placebo over six (6) months as a part of this multi-site study; (4) Shall have established inter-rater reliability on the measures used in this study, and have an ongoing collaborative relationship that will allow the successful completion of the study. It is the Government's belief that these requirements may only be met by Rhode Island Hospital. This is not a formal solicitation, however, concerns that respond to this notice must furnish concise responses directed specifically to the requirements mentioned above. Sources demonstrating the capability to accomplish the above shall supply pertinent information in sufficient detail to demonstrate their ability to perform. Information furnished shall include enough material to perform a proper evaluation. Respondents will not be notified of the evaluation results.

Bid Protests Not Available